and Vascular Disease Foundation
According to NICE guidance and MHRA safety information, healthcare professionals should maintain vigilance for rare but serious adverse effects including acute pancreatitis, gallbladder disease, and potential thyroid tumours (based on animal studies, though human risk remains uncertain)
This food effect can effectively double systemic drug exposure without changing the nominal dose an often-overlooked factor in safety discussions
Participants were randomised (4:1) to receive once-weekly subcutaneous injections of HRS9531 or placebo across four dose cohorts (1.0mg, 3.0mg, 4.5mg and 6.0mg) for 24 weeks.
The application has now entered the FDA's review phase, and the agency has advised that it expects to complete its review within approximately 45 days and grant the HDE
It does not diagnose, treat, or recommend medical use